67. Polycystic kidney disease Clinical trials / Disease details
Clinical trials : 221 / Drugs : 212 - (DrugBank : 55) / Drug target genes : 40 - Drug target pathways : 151
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | JPRN-UMIN000046275 | 2021/12/11 | 06/12/2021 | The effect of dapagliflozin in autosomal dominant polycystic kidney disease patients using tolvaptan: randomized crossover controlled trial | The effect of dapagliflozin in autosomal dominant polycystic kidney disease patients using tolvaptan: randomized crossover controlled trial - The effect of dapagliflozin in autosomal dominant polycystic kidney disease patients using tolvaptan | Autosomal dominant polycystic kidney disease (ADPKD) | Dapagliflozin 10mg/day for 6 months No treatment for 6 months | Department of Endocrinology, Metabolism and Nephrology, Keio University School of Medicine | Department of Nephrology, International University of Health and Welfare School of MedicineDivision of Nephrology, Japanese Red Cross Medical Center | Recruiting | 20years-old | Not applicable | Male and Female | 30 | Not selected | Japan |